Cardiovascular Systems (CSII) Tops Q2 EPS by 3c, Offers Q3 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Leerink Partners Cut Price Target on Cardiovascular Systems (CSII) Following Disappointing 2Q and 3Q Guidance
January 22, 2016 9:22 AM ESTLeerink Partners maintained a Market Perform rating on Cardiovascular Systems (NASDAQ: CSII), and cut the price target to $13.00 (from $17.00), following the company's 2Q earnings report. For F2Q16, CSII reported sales of $41.4M, ~$2M below consensus. Also, management guided F3Q16 revenues well below consensus, yet again, at $40.5M-$42.0M vs. the Street at $46.1M. The guidance indicated what appears to be a more protracted impact than originally expected from the ongoing... More
Needham & Company Downgrades Cardiovascular Systems (CSII) to Underperform
January 22, 2016 7:34 AM ESTNeedham & Company downgraded Cardiovascular Systems (NASDAQ: CSII) from Buy to Underperform, saying positive revenue growth may be a year away.
Analyst Mike Matson commented, "CSII's F2Q16 revenue missed and EPS beat consensus and management guided below consensus for F2Q16. We are... More
